New meta-analysis finds Perspectum’s non-invasive MRI biomarker cT1 is an effective alternative to biopsy for identifying patients at high risk of liver disease progression
OXFORD, England – January 2022. A new meta-analysis study published in the peer-reviewed journal, Clinical Gastroenterology and Hepatology, found that LiverM…
12 Jan 2022
Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health
Partnership Combines Imaging and Functional Assessment for Clinical Research San Francisco, CA and Denver, CO – Nov. 1, 2021. Perspectum and HepQuant are …
1 Nov 2021
Perspectum Expands into Louisiana in Partnership with West Jefferson Medical Center in New Orleans, LA
Dallas, TX., October 4, 2021. More than 100 million people in the United States have liver diseases and thousands die each year from chronic liver disease. &nb…
5 Oct 2021
Perspectum Announces Partnership with Datavant to Improve Clinical Trial Recruitment with Connected Data
San Francisco, CA - September 16, 2021 - Perspectum, a global quantitative and genomics-based imaging company, is joining forces with Datavant, the leader in h…
16 Sep 2021
New study finds Perspectum®’s LiverMultiScan® may positively impact patient participation in liver disease care pathways
Oxford, UK – September 2021. Perspectum®’s LiverMultiScan® significantly enhanced patient understanding of chronic liver disease (CLD) care in a first-of…
13 Sep 2021
First European guidance on the use of multiparametric MRI in fatty liver disease
Oxford, September 4th, 2020. The first European guidance using multiparametric MRI (mpMRI), including cT1® , to assess the risk of liver fibrosis and inflamma…
4 Sep 2021
Paige and Perspectum Partner to Power Late-Stage Clinical Trials with Digital Pathology
New York and San Francisco, CA – August 05, 2021. Perspectum and Paige today announced a strategic business partnership to leverage quantitative and artifici…
5 Aug 2021
New Clinical Study Investigates Using Integrated Diagnostics to Enable Precision Medicine for Liver Cancer Patients
Oxford, UK – JULY 9, 2021. Perspectum is pleased to announce that a new prospective, observational, cohort study called Precision medicine for liver tumours …
9 Jul 2021
The National Consortium for Intelligent Medical Imaging COVID Research Fund supports Perspectum’s COVERSCAN study
Oxford, June 23, 2020. We are pleased to announce Perspectum has been awarded a grant under the NCIMI COVID Research Fund to support our recently launched COVE…
23 Jun 2021
Reducing stillbirth (First PLUS) receives Phase 2 National Institute for Health Research (NIHR) Award
Oxford, UK – JUNE 17, 2021. Perspectum is pleased to announce that it has been successful in the latest round of the Artificial Intelligence in Health and Ca…
17 Jun 2021
New publication: Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis
We would like to congratulate Helena Thomaides-Brears, H.B. et al. for their publication success of "Incidence of complications from percutaneous biopsy in chr…
16 Jun 2021
New Partnership between Marubeni/Clairvo and Perspectum to bring LiverMultiScan to Japan
Oxford, UK – May 26, 2021. Perspectum announced that it has signed a strategic business partnership with Marubeni Corporation (“Marubeni”) to support ent…
26 May 2021